| Regeneron Pharmaceuticals |
| Date/Time | / |
| Chg. / Chg.(%) | - / |
| Bid | - |
| Ask | - |
| Open | - |
| Previous Close | - |
| High | - |
| Low | - |
| Volume [USD] | - |
| Volume [Units] | |
| Price fixings | |
| ISIN | US75886F1075 |
| Security | REGN |
| Exchange | IEX |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| TradeGate | 607.000 |  |
15 |
| Quotrix | 606.8000 |  |
6 |
| gettex | 607.500 | |
1 |
| Hamburg | 602.10 | |
0 |
| Hannover | 602.10 | |
0 |
| Frankfurt | 603.5000 | |
0 |
| Düsseldorf | 606.70 | |
0 |
| Berlin | 602.20 | |
0 |
| München | 609.20 | |
0 |
| Lang & Schwa.. | 605.80 | |
|
| Stuttgart | 606.400 | |
|
| NASDAQ | 623.9000 | |
468,887 |
| IEX | 624.28 | |
37,542 |
| Cboe US | 623.59 | |
16,740 |
| London Domes.. | 636.02 | 606 | |
| Xetra | 613.90 | 0 | |
| Vienna Globa.. | 615.50 | 0 |
News
- Regeneron to buy Sanofi's stake in joint project for $900M
06/02/2022 / 13:56 - TeleTrader - Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver
03/29/2022 / 03:00 - GlobeNewswire - Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
03/26/2022 / 15:00 - GlobeNewswire - Vaxxinity Appoints Dr. Peter Powchik to Board of Directors
03/21/2022 / 12:00 - GlobeNewswire - Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
02/28/2022 / 22:01 - GlobeNewswire
Real-time